PRESS RELEASES & ARTICLES
STAY UPDATED

Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients

July 19, 2019

Immatics Biotechnologies GmbH, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, NCT02876510) at the AACR Special Conference on Immune Cell Therapies for Cancer.

PDF

Immatics Appoints Harpreet Singh as Chief Executive Officer

July 08, 2019

Immatics Biotechnologies GmbH, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.

PDF

Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

April 09, 2019

Immatics, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA203 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors.

PDF

Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

February 26, 2019
PDF

US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies

January 03, 2019
PDF

Nature publication reports first-in-human trial for a personalized cancer immunotherapy

December 20, 2018
PDF

Arsanis and X4 Pharmaceuticals Agree to Merger

November 27, 2018
PDF

Opsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)

October 25, 2018
PDF

EMBL Ventures Portfolio Company, ViraTherapeutics, acquired by Boehringer Ingelheim in EUR 210 million (USD 245 million) transaction.

September 13, 2018
PDF

Crescendo Biologics Appoints Dr Pavel Pisa as Chief Medical Officer

September 11, 2018
PDF

Allecra Therapeutics Successfully Enters Next Development Phase

August 23, 2018
PDF

Immatics Enters into a Strategic Partnership with Genmab

July 12, 2018
PDF

Immatics Appoints Stephen Eck as Chief Medical Officer US

May 14, 2018
PDF

Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing

April 30, 2018
PDF

Topas Therapeutics and BI Sign Multi-Year Collaboration and Option Agreement

April 24, 2018
PDF

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2

March 26, 2018
PDF

ViraTherapeutics starts 2nd development program with Boehringer Ingelheim

March 12, 2018
PDF

Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic

February 15, 2018
PDF

Topas Therapeutics serves as exclusive translational partner for CRC

January 25, 2018
PDF

Immatics Proprietary Target Selected for the Devel. of Cancer Immunotherapies

December 21, 2017
PDF

Immatics Appoints Thomas Ulmer as CFO

December 19, 2017
PDF

Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

December 19, 2017
PDF

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2

December 08, 2017
PDF

Allecra Therapeutics Announces New Staged Financing Deal

December 04, 2017
PDF

Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017

November 30, 2017
PDF

Arsanis Announces Closing of Initial Public Offering

November 20, 2017
PDF

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

November 13, 2017
PDF

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

November 02, 2017
PDF

Topas Therapeutics Appoints Rupert Sandbrink as CDO and CMO

October 26, 2017
PDF

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

October 04, 2017
PDF

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®

September 28, 2017
PDF

Allecra Announces Initiation of a Phase 2 Clinical Trial

September 07, 2017
PDF

Immatics Initiates a Phase I trial using ACTolog

August 22, 2017
PDF

Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards

June 16, 2017
PDF

EMBL Ventures portfolio company Luxendo acquired by Bruker

May 08, 2017
PDF

Arsanis Completes $45.5 Million Series D Financing

April 26, 2017
PDF

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

April 04, 2017
PDF

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

April 04, 2017
PDF

Arsanis and Adimab Enter Into License Agreement

February 27, 2017
PDF

Arsanis Announces First Patient Dosed in Global Phase 2 Study

January 24, 2017
PDF

Crescendo partners with Genedata

January 10, 2017
PDF

Luxendo announces Series A extension

January 09, 2017
PDF

Opsona announces preliminary MDS results

December 20, 2016
PDF

Opsona receives orphan designation

October 25, 2016
PDF

Crescendo enters a collaboration with Takeda

October 10, 2016
PDF

ViraT enters collaboration with Boehringer Ingelheim

September 28, 2016
PDF

Crescendo strengthens IP portfolio

September 27, 2016
PDF

Topas Series A Financing

March 22, 2016
PDF
© EMBL Ventures 2019